Recruiting

Precision Cancer Medicine

Sponsor:

Ohio State University Comprehensive Cancer Center

Code:

NCT02090530

Conditions

Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen collection

Study Details

Brief summary:

Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing

Conditions

Cancer

Study ID

NCT02090530

Start date

Nov 4, 2013

Status verified date

Apr, 2026

Completion date

Dec 31, 2027

Anticipated

Primary completion date

Dec 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. A histologically or cytologically confirmed diagnosis of cancer
2. Patients with any malignancy.
3. Patients must have tumor suitable for research tumor biopsy (as assessed by trained specialists in interventional radiology) and Patients are medically fit to undergo a tissue biopsy or surgical procedure to get tumor tissue OR If Patients do not have a tumor suitable for biopsy but have another tissue available for molecular evaluation.

OR Patients are undergoing standard of care surgeries or procedures where fresh specimens will be first used for routine pathologic assessment and only then will leftover tissue be used for research purposes.
4. Procedure-specific signed informed consent prior to initiation of any study-related procedures.
5. Women and minorities are included in this protocol.
6. Patients with multiple malignancies remain eligible.
7. Patients with an inherited cancer syndrome or a medical history suggestive of an inherited cancer syndrome remain eligible.

Exclusion Criteria:

1. It is the enrolling study physicians discretion to decide if a patient is not fit enough to undergo tissue biopsy.
2. Patients who are incarcerated are not eligible to participate.

Study Design

Enrollment

1000 participants

Anticipated

Interventions and Outcome Measures

Arms

Advanced Cancer Patients

Individuals with advanced or refractory cancer must be identified by study personnel or their treating physician, deemed eligible for this study, and voluntarily agree to be enrolled in this protocol through an informed consent. Biospecimen collection includes a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.

Interventions

Biospecimen collection

Specimens to be collected include a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.

Primary outcome measure

  • Number of participants receiving new therapy based on study findings [ Time Frame: Up to 24 Months ]

Central Contacts and Locations

Central contacts

Ohio State University Comprehensive Cancer Center

1-800-293-5066OSUCCCClinicaltrials@osumc.edu

Sameek Roychowdhury, MD, PhD

614-685-5842Sameek.Roychowdhury@osumc.edu

Locations

Ohio State University Wexner Medical Center

Recruiting

Columbus, Ohio, United States, 43210

Contacts

Sameek Roychowdhury, MD, PhD

614-685-5842Sameek.Roychowdhury@osumc.edu

Principal Investigator:

Sameek Roychowdhury, MD, PhD

More Information

Sponsor

Ohio State University Comprehensive Cancer Center

Last update posted

Apr 8, 2026

Last verified

Apr, 2026

Keywords

  • Cancer Genomics
  • Tumor Sequencing

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Ohio State University Comprehensive Cancer Center on 2026-04-08.